PE/VC investors
Private Equity (PE) and Venture Capital (VC) investors are the catalysts of innovation and growth in the business world. PE firms primarily target established companies, seeking to optimize operations and unlock value through strategic investments and management expertise. They focus on long-term growth and profitability, often preparing businesses for a future sale or IPO. VC investors, by contrast, are the adventurers of finance, injecting capital into high-potential startups and early-stage companies. They embrace risk for the possibility of outsized returns, often becoming invaluable advisors. Both investor types not only bring capital but also strategic guidance, industry connections, and market insights, propelling their portfolio companies towards success.
Investors (6,250)
Investor
Description
More information
Bioeconomy Capital
Bioeconomy Capital (BeC) invests in early stage companies with the goal of accelerating the biotechnology revolution. Based on our startup operational expertise, product development experience, and globally recognized strategic analysis, we have developed a blueprint for building and deploying technological capabilities that will become critical infrastructure of the 21st century economy. This proprietary blueprint is the distillation of the fund managers' five decades of combined experience in synthetic biology and other engineering fields and cannot be readily duplicated. Prior investments include Zymergen, Riffyn, Synthace, RoosterBio, Arzeda, Bellwether Bio, EdenWorks, and Lumen Biosciences
BioGeneration Ventures
![BioGeneration Ventures]()
BioGeneration Ventures (BGV) is a venture capital company, with a focus on early stage European biotech, medtech, and diagnostics companies. BGV has a strong track record of significant financial returns through investing in innovations in healthcare and providing the expertise to build world-class teams. The Company manages over €100 million of funds investing in areas where true scientific innovations, the unmet medical need, and the potential to demonstrate a significant proof of concept all come together.
BGV strives to work with founding teams to mature science and build companies. The Company uses its experience to guide progress into clinical trials, ultimately leading to successful drug development and value realisation for its investors. BGV applies its expertise in a rigorous process to select the most compelling opportunities with the best prospects for exit.
Historical successful investments include divestment of Dezima Pharma to Amgen for up to USD 1.55 billion in total deal value and in Acerta Pharma for up to USD 7 billion with a guaranteed payment of USD 4 billion. Both companies were co-founded by BGV in 2012 and 2013 respectively. The Acerta Pharma sale was the largest exit ever of a privately held European biotech company.
BGV is based in Naarden, The Netherlands, and closely collaborates with Forbion.
BioInnovation Capital
BioInnovation Capital invests in the most promising life science companies in residence at premier co-working laboratory facilities where our partners are on-site every day. As the first investment platform to knit together a national network of co-working laboratories, we have a unique lens and an unparalleled position from which to invest. Our perspective is characterized by superb access to key innovators in academia, as well as to the corporate partners who are likely eventual homes for our investments. The geographic nature of innovation hubs and our overlapping network of facilities and resources, supports the formation of stellar companies from the most powerful universities, research institutions, hospitals and corporations in our sector.
Bioprocess Capital Ventures
The limited liability company Management Company Bioprocess Capital Partners was established on October 6, 2006 to manage the funds of Russian venture company (RVC). Bioprocess Capital Ventures focused on biomedical and fine chemistry startups.
BioRock Ventures
BioRock Ventures invests in bio-pharma startups. Seed-sized investments into private life science companies developing novel FDA regulated therapeutic drugs. Angel, Seed, Series A, through pre-IPO/M&A. All disease areas, all stages, all therapeutic modalities.
Bios Partners
Bios Partners is a private equity firm based in Dallas/Fort Worth. Bios Partners invests in early seed opportunities as well as later stage growth companies, with a focus on biotech and medical devices companies.
<br />
BioStar Ventures
BioStar Ventures is a strategic venture capital partnership focused on accelerating value creation for medical device technologies in cardiovascular and orthopaedic medicine. Combining the insight of seasoned venture capitalists and world-renowned medical thought leaders, BioStar Ventures identifies proprietary technologies that meet unmet patient needs, as well as the acquisition criteria of major medical device companies, and then acts as a true value-added investor, providing both capital and clinical expertise to mitigate risk, optimize product development and secure successful exit.
Biotechnology Fund
Iran Biotech Fund invest in Iran and Iran related biotechnology and pharmaceutical companies with exceptional technologies or product opportunities based on strong scientific rationale and commercial potential.
<br />
Our key asset is a unique team of nearly 25 Venture Advisers, comprised of renowned industry leaders and professionals who, together with the fund’s managing partners, provide our portfolio companies with hands-on guidance and support.
<br />
We provide our portfolio companies with the necessary resources for long-term sustainable growth. We provide them with access to network, executive talent, strategic, operational, and business development resources.
BioVentures Investors
Bioventures Investers is a private equity firm that offers venture capital investment services for firms in the life sciences and healthcare industries. It was founded by Marc Goldberg and is based in Massachusetts. BioVentures Investors has forged a reputation of trust, integrity, performance and professionalism that is sought after by the leadership of emerging medtech companies.
BIP Capital LLC
BIP Capital is recognized as one of the most active Venture Capital firms in the Southeast, serving entrepreneurs, investors, and operators to grow the emerging company ecosystem in our geographic area. We apply experience and process to make both investment decisions and operational recommendations, allowing our portfolio companies to get and stay on a glide path of growth.
<br />
